The PPLP-217™ strain of L. plantarum has been the focus of ground-breaking studies in neonates and young infants which were conducted by Dr. Pinaki Panigrahi, MD, PhD, FIDSA, a world-renowned pediatric infectious disease expert.
The most recent research was a randomized, double-blind, placebo-controlled clinical trial of 4,556 infants within the first two months of life. The treatment was so successful that an oversight panel stopped the trial early as it would have been unethical to continue depriving half the newborns of the probiotic.
The results of this trial were published in the prestigious journal Nature and has been cited over 125 times. Discover magazine selected the work as one of 100 most interesting scientific stories of the year. The clinical trial and its ramifications were covered by The New York Times, The Atlantic, NPR and other major newspapers around the world.
Clinically Supported Benefits
- Supports healthy growth in the first days of life
- Assists a developing digestive system
- Helps promote a healthy immune system
- Shown to support respiratory tract health
- Proven safe for infants
A Greater Cause
Understanding the potential worldwide social impact, a percentage of all L. plantarum PPLP-217 sales will be given to the Healthy Bellies, Healthy Babies Foundation whose sole focus is providing this strain to neonates, infants and families in need.